IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8-IL-17-producing T cells

Journal of Immunology

Volumn 193, Issue 5, 2014, Pages 2168-2177

  Mizui, Masayuki ^a   Koga, Tomohiro ^a   Lieberman, Linda A ^a   Beltran, Jessica ^a   Yoshida, Nobuya ^a   Johnson, Mark C ^b   Tisch, Roland ^b,c   Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 MONOCLONAL ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; MONOCLONAL ANTIBODY; PARVOVIRUS VECTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IL2RB PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DEATH; CELL EXPANSION; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DRUG MECHANISM; FEMALE; KIDNEY DISEASE; LUNG DISEASE; LYMPHADENOPATHY; MONONUCLEAR CELL; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; REGULATORY T LYMPHOCYTE; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; ANTINEOPLASTIC AGENTS; FEMALE; INTERLEUKIN-17; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; T-LYMPHOCYTES, REGULATORY;

EID: 84907023082     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400977     Document Type: Article

References (52)

1. Tsokos, G. C. 2011. Systemic lupus erythematosus. N. Engl. J. Med. 365: 2110-2121.
2. Liu, Z., and A. Davidson. 2012. Taming lupus: a new understanding of pathogenesis is leading to clinical advances. Nat. Med. 18: 871-882.
3. Lewis, J. E., S. M. Fu, and F. Gaskin. 2013. Autoimmunity, end organ damage, and the origin of autoantibodies and autoreactive T cells in systemic lupus erythematosus. Discov. Med. 15: 85-92.
4. Ortega, L. M., D. R. Schultz, O. Lenz, V. Pardo, and G. N. Contreras. 2010. Review: lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 19: 557-574.
5. Fossati, L., S. Takahashi, R. Merino, M. Iwamoto, J. P. Aubry, M. Nose, C. Spach, R. Motta, and S. Izui. 1993. An MRL/MpJ-lpr/lpr substrain with a limited expansion of lpr double-negative T cells and a reduced autoimmune syndrome. Int. Immunol. 5: 525-532.
6. Kinjyo, I., S. M. Gordon, A. M. Intlekofer, K. Dowdell, E. C. Mooney, R. Caricchio, S. A. Grupp, D. T. Teachey, V. K. Rao, T. Lindsten, and S. L. Reiner. 2010. Cutting edge: lymphoproliferation caused by Fas deficiency is dependent on the transcription factor eomesodermin. J. Immunol. 185: 7151-7155.
7. Nowling, T. K., and G. S. Gilkeson. 2011. Mechanisms of tissue injury in lupus nephritis. Arthritis Res. Ther. 13: 250.
8. Theofilopoulos, A. N., R. Kofler, P. A. Singer, and F. J. Dixon. 1989. Molecular genetics of murine lupus models. Adv. Immunol. 46: 61-109.
9. Davidson, A., and C. Aranow. 2010. Lupus nephritis: lessons from murine models. Nat. Rev. Rheumatol. 6: 13-20.
10. Laurence, A., C. M. Tato, T. S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R. B. Blank, F. Meylan, R. Siegel, L. Hennighausen, et al. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26: 371-381.
11. Liao, W., J. X. Lin, and W. J. Leonard. 2013. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38: 13-25.
12. Refaeli, Y., L. Van Parijs, C. A. London, J. Tschopp, and A. K. Abbas. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8: 615-623.
13. Yang, X. P., K. Ghoreschi, S. M. Steward-Tharp, J. Rodriguez-Canales, J. Zhu, J. R. Grainger, K. Hirahara, H. W. Sun, L. Wei, G. Vahedi, et al. 2011. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12: 247-254.
14. Ballesteros-Tato, A., B. León, B. A. Graf, A. Moquin, P. S. Adams, F. E. Lund, and T. D. Randall. 2012. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36: 847-856.
15. Sadlack, B., J. Löhler, H. Schorle, G. Klebb, H. Haber, E. Sickel, R. J. Noelle, and I. Horak. 1995. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 25: 3053-3059.
16. Gómez-Martín, D., M. Díaz-Zamudio, J. C. Crispín, and J. Alcocer-Varela. 2009. Interleukin 2 and systemic lupus erythematosus: beyond the transcriptional regulatory net abnormalities. Autoimmun. Rev. 9: 34-39.
17. Lieberman, L. A., and G. C. Tsokos. 2010. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J. Biomed. Biotechnol. 2010: 740619.
18. Humrich, J. Y., H. Morbach, R. Undeutsch, P. Enghard, S. Rosenberger, O. Weigert, L. Kloke, J. Heimann, T. Gaber, S. Brandenburg, et al. 2010. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl. Acad. Sci. USA 107: 204-209.
19. Koga, T., K. Ichinose, M. Mizui, J. C. Crispín, and G. C. Tsokos. 2012. Calcium/ calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus. J. Immunol. 189: 3490-3496.
20. Mellor-Pita, S., M. J. Citores, R. Castejon, P. Tutor-Ureta, M. Yebra-Bango, J. L. Andreu, and J. A. Vargas. 2006. Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 65: 553-554.
21. Wong, C. K., L. C. Lit, L. S. Tam, E. K. Li, P. T. Wong, and C. W. Lam. 2008. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus:implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol. 127: 385-393.
22. Crispín, J. C., M. Oukka, G. Bayliss, R. A. Cohen, C. A. Van Beek, I. E. Stillman, V. C. Kyttaris, Y. T. Juang, and G. C. Tsokos. 2008. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181: 8761-8766.
23. Zhang, Z., V. C. Kyttaris, and G. C. Tsokos. 2009. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 183: 3160-3169.
24. Crispín, J. C., and G. C. Tsokos. 2009. Human TCR-alpha beta+ CD42 CD82 T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J. Immunol. 183: 4675-4681.
25. Boyman, O., M. Kovar, M. P. Rubinstein, C. D. Surh, and J. Sprent. 2006. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927.
26. Boyman, O., and J. Sprent. 2012. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12: 180-190.
27. Koreth, J., K. Matsuoka, H. T. Kim, S. M. McDonough, B. Bindra, E. P. Alyea, III, P. Armand, C. Cutler, V. T. Ho, N. S. Treister, et al. 2011. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365: 2055-2066.
28. Matsuoka, K., J. Koreth, H. T. Kim, G. Bascug, S. McDonough, Y. Kawano, K. Murase, C. Cutler, V. T. Ho, E. P. Alyea, et al. 2013. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graftversus- host disease. Sci. Transl. Med. 5: 179ra43.
29. Saadoun, D., M. Rosenzwajg, F. Joly, A. Six, F. Carrat, V. Thibault, D. Sene, P. Cacoub, and D. Klatzmann. 2011. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365: 2067-2077.
30. Bluestone, J. A. 2011. The yin and yang of interleukin-2-mediated immunotherapy. N. Engl. J. Med. 365: 2129-2131.
31. Gutierrez-Ramos, J. C., J. L. Andreu, Y. Revilla, E. Viñuela, and C. Martinez. 1990. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 346: 271-274.
32. Gutierrez-Ramos, J. C., J. L. Andreu, M.A. Marcos, I. R. Vegazo, and C. Martinez. 1991. Treatment with IL2/vaccinia recombinant virus leads to serologic, histologic and phenotypic normalization of autoimmune MRL/lpr-lpr mice. Autoimmunity 10: 15-25.
33. Goudy, K. S., M. C. Johnson, A. Garland, C. Li, R. J. Samulski, B. Wang, and R. Tisch. 2011. Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes. J. Immunol. 186: 3779-3786.
34. Kulkarni, O. P., M. Ryu, C. Kantner, M. Sárdy, D. Naylor, D. Lambert, R. Brown, and H. J. Anders. 2012. Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice. Nephrol. Dial. Transplant. 27: 1358-1367.
35. Benihoud, K., D. Bonardelle, P. Bobé, and N. Kiger. 1997. MRL/lpr CD42 CD82 and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways. Eur. J. Immunol. 27: 415-420.
36. Clementi, R., A. Chiocchetti, G. Cappellano, E. Cerutti, M. Ferretti, E. Orilieri, I. Dianzani, M. Ferrarini, M. Bregni, C. Danesino, et al. 2006. Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function. Blood 108: 3079-3084.
37. Lahoud, M. H., A. I. Proietto, K. H. Gartlan, S. Kitsoulis, J. Curtis, J. Wettenhall, M. Sofi, C. Daunt, M. O'keeffe, I. Caminschi, et al. 2006. Signal regulatory protein molecules are differentially expressed by CD82 dendritic cells. J. Immunol. 177: 372-382.
38. Yamaguchi, T., J. B. Wing, and S. Sakaguchi. 2011. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or noninflammatory conditions. Semin. Immunol. 23: 424-430.
39. Tsokos, G. C., and J. E. Balow. 1981. Cytotoxic responses to alloantigens in systemic lupus erythematosus. J. Clin. Immunol. 1: 208-216.
40. Peng, S. L., J. Moslehi, M. E. Robert, and J. Craft. 1998. Perforin protects against autoimmunity in lupus-prone mice. J. Immunol. 160: 652-660.
41. Shevach, E. M. 2012. Application of IL-2 therapy to target T regulatory cell function. Trends Immunol. 33: 626-632.
42. Webster, K. E., S. Walters, R. E. Kohler, T. Mrkvan, O. Boyman, C. D. Surh, S. T. Grey, and J. Sprent. 2009. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206: 751-760.
43. Penaud-Budloo, M., C. Le Guiner, A. Nowrouzi, A. Toromanoff, Y. Chérel, P. Chenuaud, M. Schmidt, C. von Kalle, F. Rolling, P. Moullier, and R. O. Snyder. 2008. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J. Virol. 82: 7875-7885.
44. Flierl, A., Y. Chen, P. E. Coskun, R. J. Samulski, and D. C. Wallace. 2005. Adeno-associated virus-mediated gene transfer of the heart/muscle adenine nucleotide translocator (ANT) in mouse. Gene Ther. 12: 570-578.
45. Odegard, J. M., B. R. Marks, L. D. DiPlacido, A. C. Poholek, D. H. Kono, C. Dong, R. A. Flavell, and J. Craft. 2008. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J. Exp. Med. 205: 2873-2886.
46. Zeller, G. C., J. Hirahashi, A. Schwarting, A. H. Sharpe, and V. R. Kelley. 2006. Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus. J. Am. Soc. Nephrol. 17: 122-130.
47. Hsieh, C., A. Chang, D. Brandt, R. Guttikonda, T. O. Utset, and M. R. Clark. 2011. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res. 63: 865-874.
48. Pisitkun, P., H. L. Ha, H. Wang, E. Claudio, C. C. Tivy, H. Zhou, T. N. Mayadas, G. G. Illei, and U. Siebenlist. 2012. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 37: 1104-1115.
49. Amadi-Obi, A., C. R. Yu, X. Liu, R. M. Mahdi, G. L. Clarke, R. B. Nussenblatt, I. Gery, Y. S. Lee, and C. E. Egwuagu. 2007. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 13:711-718.
50. Kayagaki, N., N. Yamaguchi, M. Nakayama, K. Takeda, H. Akiba, H. Tsutsui, H. Okamura, K. Nakanishi, K. Okumura, and H. Yagita. 1999. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163: 1906-1913.
51. Puliaeva, I., R. Puliaev, and C. S. Via. 2009. Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE. Autoimmun. Rev. 8: 219-223.
52. Tang, Q., K. J. Henriksen, M. Bi, E. B. Finger, G. Szot, J. Ye, E. L. Masteller, H. McDevitt, M. Bonyhadi, and J. A. Bluestone. 2004. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199: 1455-1465.